PDGF-BB: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

Target Name: NDUFAF2

NCBI ID: G91942

NDUFAF2

PDGF-BB: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

Native Developmental Umbilical Artery F2 (NDUFAF2) is a gene that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 6 and encodes a protein known as PDGF -BB (Platelet-derived growth factor-B).

PDGF-BB is a critical signaling molecule that plays a vital role in the development and maintenance of tissues and organs, including blood vessels, neurons, and tissues. It is involved in several physiological processes, including cell growth, differentiation, and angiogenesis. PDGF -BB has also been implicated in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of PDGF-BB is its ability to promote the growth and survival of cancer cells. Studies have shown that high levels of PDGF-BB have been observed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting PDGF-BB may be an effective way to treat these diseases.

Another function of PDGF-BB is its role in the development and progression of neurodegenerative diseases. These conditions include Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that PDGF-BB is involved in the development of neurodegenerate plaque (neuronal loss ) and that it may also contribute to the progression of these conditions.

PDGF-BB has also been implicated in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions involve an overactive immune system that can cause inflammation and damage to tissues and organs. Studies have shown that PDGF-BB is involved in the development and maintenance of immune cells and that it may contribute to the development of autoimmune disorders.

In addition to its role in disease progression, PDGF-BB has also been shown to have potential therapeutic benefits. For example, studies have shown that inhibiting PDGF-BB can be an effective way to treat certain types of cancer, including breast and ovarian cancer . Additionally, PDGF-BB has been shown to be a potential biomarker for several types of cancer, including breast and ovarian cancer.

In conclusion, NDUFAF2 (Mimitin) is a gene that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions as a signaling molecule and its involvement in the development and progression of these conditions make it an attractive target for therapeutic intervention. Further research is needed to fully understand the role of PDGF-BB in these diseases and to develop effective treatments.

Protein Name: NADH:ubiquinone Oxidoreductase Complex Assembly Factor 2

Functions: Acts as a molecular chaperone for mitochondrial complex I assembly (PubMed:16200211, PubMed:19384974). Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (PubMed:16200211, PubMed:27626371)

The "NDUFAF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDUFAF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets